Aspirin is a cornerstone of therapy in the treatment of patients with acute coronary
syndromes (ACS). However, dual antiplatelet therapy reduces the risk of stent thrombosis …

Antithrombotic therapy is imperative in the management of patients presenting with an acute
coronary syndrome (ACS). The combination of antiplatelet therapy in conjunction with …

A review of the literature was conducted for clinical trials evaluating the antiplatelet P2Y12
receptor antagonists, clopidogrel, prasugrel, and ticagrelor, as well as the guidelines for the …

OBJECTIVE: Dual antiplatelet therapy (DAPT) is the treatment of choice in the medical
management of patients with acute coronary syndrome (ACS). The combination of aspirin …

Introduction: Coronary thrombosis is a frequent cause of death and myocardial infarction
most often explained by superimposition of a platelet-rich thrombus on existing coronary …

Dual antiplatelet therapy with Aspirin and Clopidogrel has been considered as a
cornerstone therapy after acute coronary syndrome (ACS)[1] before new P2Y12 blockers …

BACKGROUND: Clopidogrel is beneficial after ACS. Recent data suggest the superiority of
prasugrel or ticagrelor compared with clopidogrel. However, there is no comparison of …

Dual antiplatelet therapy is the cornerstone in the management of patients with acute
coronary syndromes (ACS). Ticagrelor, an oral, direct, reversibly binding, P2Y 12 receptor …

Background We aimed to compare the clinical outcomes of clopidogrel, prasugrel, and
ticagrelor in clinical practice using the National Cardiovascular Database ACTION …

Background Guidelines recommend prasugrel or ticagrelor instead of clopidogrel in patients
with acute coronary syndromes (ACS) undergoing percutaneous coronary interventions …